Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(19):1504; doi:10.1093/jnci/94.19.1504
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vogel, V. G.
Right arrow Articles by Cronin, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogel, V. G.
Right arrow Articles by Cronin, W. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 19, 1504, October 2, 2002
© 2002 Oxford University Press

CORRESPONDENCE

Re: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Victor G. Vogel, Joseph P. Costantino, D. Lawrence Wickerham, Walter M. Cronin

Affiliations of authors: V. Vogel, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene Trial; J. P. Costantino, D. L. Wickerham, W. M. Cronin, National Surgical Adjuvant Breast and Bowel Project.

Correspondence to: Victor G. Vogel, M.D., M.H.S., F.A.C.P., University of Pittsburgh Cancer Institute/Magee-Women's Hospital, 300 Halket St., Rm. 3524, Pittsburgh, PA 15213 (e-mail: vvogel@mail.magee.edu).

The first 10% of the full text of this article appears below.

Tamoxifen reduces the development of invasive breast cancer in women at high risk for the disease (1). The Breast Cancer Prevention Trial (BCPT) demonstrated a 49% reduction of invasive breast cancer incidence in all high-risk women randomly assigned to receive tamoxifen and an even larger 86% reduction in invasive breast . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
C J Fabian, B F Kimler, M S Mayo, and S A Khan
Breast-tissue sampling for risk assessment and prevention
Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Tice, R. Miike, K. Adduci, N. L. Petrakis, E. King, and M. R. Wrensch
Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 324 - 328.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. N. Peshkin, C. Isaacs, C. Finch, S. Kent, and M. D. Schwartz
Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians
J. Clin. Oncol., December 1, 2003; 21(23): 4322 - 4328.
[Abstract] [Full Text] [PDF]